| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 16,583.0 | 16,654.0 |
| Profit before tax | 3,385.0 | 3,334.0 |
| Net income | 3,242.0 | 3,541.0 |
| EPS (diluted, $ a share) | $0.56 | $0.62 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -8.4% |
|---|---|
| Revenue, year on year | -0.4% |
10-Q filed with the SEC, NYSE: PFE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pfizer Inc: key numbers
- Share price
- $28.86Close, Nov 16
- Market cap
- $164B
- Shares outstanding
- 5.7BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pfizer Inc
All →Pfizer Leadership Change
Pfizer Inc. has appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Ms. Guegan, who had been serving as Interim CFO since August 2026, will receive an annual base salary of $1.3 million and a target cash incentive opportunity of 100% of her base salary.
Pfizer Financial Results
Pfizer reported Q3 2026 revenues of $16.6 billion, with 32% operational growth from launched and acquired products. The company raised its full-year 2026 revenue guidance to $62.0-$64.0 billion and appointed Cecile Guegan as its new Chief Financial Officer.
- Term
- Q3 2026
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”
Dr. Albert Bourla, Chairman and CEO of Pfizer
“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products. Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”
Cecile Guegan, CFO and EVP of Pfizer